Benralizumab (anti-IL5RA ), CAS 1044511-01-4

Product Description: Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study [1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5(3):00009-2019. Published 2019 Sep 25./[2]Kolbeck R, et al. MEDI-563, a humanized anti-IL-5receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicityfunction. J Allergy Clin Immunol. 2010;125(6):1344-1353.e2.

CAS Number: 1044511-01-4

Molecular Weight: N/A

Compound Purity: 99.60

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Interleukin Related

• Artikelnummer: MEXHY-P9923A-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9923A-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK